Trump Administration Links Tylenol Use During Pregnancy to Autism, Proposes Leucovorin as Treatment

The Trump administration is set to announce a controversial link between the use of acetaminophen (Tylenol) during pregnancy and an increased risk of autism in children. Additionally, the administration plans to propose leucovorin, a form of folic acid typically used to mitigate chemotherapy side effects, as a potential treatment for autism.

President Donald Trump previewed the announcement, stating, "I think we found an answer to autism." Health and Human Services Secretary Robert F. Kennedy Jr. has prioritized identifying the causes of autism, previously pledging to determine the cause by September.

Medical experts and the pharmaceutical industry have expressed strong opposition to these claims. Kenvue, the manufacturer of Tylenol, stated, "We strongly disagree with any suggestion" that acetaminophen use during pregnancy causes autism. The American College of Obstetricians and Gynecologists noted, "There is no clear evidence that proves a direct relationship between the prudent use of acetaminophen during pregnancy and fetal developmental issues."

Scientific studies on the link between acetaminophen use during pregnancy and autism have yielded mixed results. Some research suggests a potential association, while others find no significant connection. Medical professionals continue to recommend acetaminophen as a safe option for managing pain and fever during pregnancy, emphasizing that untreated fever can pose risks to both mother and child.

Regarding leucovorin, while some studies indicate it may improve communication skills in children with autism, experts caution that the research is still in early stages and more studies are necessary before a definitive conclusion can be reached.

The administration's forthcoming announcement is expected to reignite debates over the causes and treatments of autism, highlighting the ongoing tension between political initiatives and established medical consensus.